251 related articles for article (PubMed ID: 22211920)
1. SPECT study of the nigrostriatal dopaminergic system in Huntington's disease.
Hwang WJ; Yao WJ
J Neuroimaging; 2013 Apr; 23(2):192-6. PubMed ID: 22211920
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study.
Verstappen CC; Bloem BR; Haaxma CA; Oyen WJ; Horstink MW
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):502-7. PubMed ID: 17053905
[TBL] [Abstract][Full Text] [Related]
3. Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study.
Yang YK; Yu L; Yeh TL; Chiu NT; Chen PS; Lee IH;
Am J Psychiatry; 2004 Aug; 161(8):1496-8. PubMed ID: 15285982
[TBL] [Abstract][Full Text] [Related]
4. [99mTc]TRODAT-1/[123I]IBZM SPECT studies of the dopaminergic system in Tourette syndrome.
Hwang WJ; Yao WJ; Fu YK; Yang AS
Psychiatry Res; 2008 Feb; 162(2):159-66. PubMed ID: 18248965
[TBL] [Abstract][Full Text] [Related]
5. Nigral involvement and nigrostriatal dysfunction in Huntington's disease: evidences from an MRI and SPECT study.
Kiferle L; Mazzucchi S; Unti E; Pesaresi I; Fabbri S; Nicoletti V; Volterrani D; Cosottini M; Bonuccelli U; Ceravolo R
Parkinsonism Relat Disord; 2013 Sep; 19(9):800-5. PubMed ID: 23769177
[TBL] [Abstract][Full Text] [Related]
6. Substantia nigra echogenicity and imaging of striatal dopamine transporters in Parkinson's disease: a cross-sectional study.
Bor-Seng-Shu E; Pedroso JL; Felicio AC; de Andrade DC; Teixeira MJ; Braga-Neto P; Batista IR; Barsottini OG; Borges V; Ferraz HB; Shih MC; Bressan RA; de Andrade LA; Walter U
Parkinsonism Relat Disord; 2014 May; 20(5):477-81. PubMed ID: 24629800
[TBL] [Abstract][Full Text] [Related]
7. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease.
Ichise M; Toyama H; Fornazzari L; Ballinger JR; Kirsh JC
J Nucl Med; 1993 Aug; 34(8):1274-81. PubMed ID: 8326384
[TBL] [Abstract][Full Text] [Related]
8. FP-CIT- and IBZM-SPECT in Corticobasal Syndrome: Results from a Clinical Follow-Up Study.
Hammesfahr S; Antke C; Mamlins E; Beu M; Wojtecki L; Ferrea S; Dinkelbach L; Moldovan AS; Schnitzler A; Müller HW; Südmeyer M
Neurodegener Dis; 2016; 16(5-6):342-7. PubMed ID: 26978429
[TBL] [Abstract][Full Text] [Related]
9. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy.
Knudsen GM; Karlsborg M; Thomsen G; Krabbe K; Regeur L; Nygaard T; Videbaek C; Werdelin L
Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1631-8. PubMed ID: 15583914
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects.
Weng YH; Yen TC; Chen MC; Kao PF; Tzen KY; Chen RS; Wey SP; Ting G; Lu CS
J Nucl Med; 2004 Mar; 45(3):393-401. PubMed ID: 15001678
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.
Scherfler C; Scholz SW; Donnemiller E; Decristoforo C; Oberladstätter M; Stefanova N; Diederen E; Virgolini I; Poewe W; Wenning GK
Neuroimage; 2005 Feb; 24(3):822-31. PubMed ID: 15652317
[TBL] [Abstract][Full Text] [Related]
12. Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease.
Hwang WJ; Yao WJ; Wey SP; Ting G
J Nucl Med; 2004 Feb; 45(2):207-13. PubMed ID: 14960637
[TBL] [Abstract][Full Text] [Related]
13. Decreased dopamine transporter availability in male smokers -- a dual isotope SPECT study.
Yang YK; Yao WJ; Yeh TL; Lee IH; Chen PS; Lu RB; Chiu NT
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):274-9. PubMed ID: 17900774
[TBL] [Abstract][Full Text] [Related]
14. Effects of C825T polymorphism of the GNB3 gene on availability of dopamine transporter in healthy volunteers--a SPECT study.
Chen PS; Yeh TL; Lee IH; Lin CB; Tsai HC; Chen KC; Chiu NT; Yao WJ; Yang YK; Chou YH
Neuroimage; 2011 Jun; 56(3):1526-30. PubMed ID: 21371559
[TBL] [Abstract][Full Text] [Related]
15. Dual SPECT of dopamine system using [99mTc]TRODAT-1 and [123I]IBZM in normal and 6-OHDA-lesioned formosan rock monkeys.
Ma KH; Huang WS; Chen CH; Lin SZ; Wey SP; Ting G; Wang SD; Liu HW; Liu JC
Nucl Med Biol; 2002 Jul; 29(5):561-7. PubMed ID: 12088726
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic function in a family with the PARK6 form of autosomal recessive Parkinson's syndrome.
Kessler KR; Hamscho N; Morales B; Menzel C; Barrero F; Vives F; Gispert S; Auburger G
J Neural Transm (Vienna); 2005 Oct; 112(10):1345-53. PubMed ID: 15785866
[TBL] [Abstract][Full Text] [Related]
17. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
Suzuki M; Desmond TJ; Albin RL; Frey KA
Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological challenge and synaptic response - assessing dopaminergic function in the rat striatum with small animal single-photon emission computed tomography (SPECT) and positron emission tomography (PET).
Nikolaus S; Larisch R; Vosberg H; Beu M; Wirrwar A; Antke C; Kley K; Silva MA; Huston JP; Müller HW
Rev Neurosci; 2011; 22(6):625-45. PubMed ID: 22103308
[TBL] [Abstract][Full Text] [Related]
19. Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients.
Huang WS; Chiang YH; Lin JC; Chou YH; Cheng CY; Liu RS
J Nucl Med; 2003 Jul; 44(7):999-1005. PubMed ID: 12843212
[TBL] [Abstract][Full Text] [Related]
20. Investigating the role of 99mTc-TRODAT-1 SPECT imaging in idiopathic Parkinson's disease.
Geng Y; Shi GH; Jiang Y; Xu LX; Hu XY; Shao YQ
J Zhejiang Univ Sci B; 2005 Jan; 6(1):22-7. PubMed ID: 15593387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
